Dear Friends and Colleagues,

It is a great pleasure to send you the latest newsletter of the Acute Leukemia Working Party (ALWP) of the EBMT, presenting structure and update of our continuously increasing activity.

In the era of rapidly developing targeted therapies, the role of HSCT is being questioned in many fields of onco-hematology. However, this is not the case for acute leukemias, where the number of HSCT procedures is continuously increasing, as reflected by growing content of our registry. In fact, the introduction of novel agents used in first line treatment or as a salvage allows higher proportion of patients reaching HSCT in remission. Their use as post-transplant maintenance may further contribute to improved outcome. In parallel, conditioning regimens evolve and become less toxic, which allows wider population of older patients to be treated with HSCT. Finally, increasing number of registered unrelated volunteers is associated with higher chance to find a donor. For patients lacking an HLA matched donor, rapidly developing strategies of haploidentical transplantations appear an attractive alternative. Altogether, HSCT for acute leukemias becomes a very exciting area of investigation and ALWP provides a proper platform for both prospective and retrospective research.

Although currently, over 70 studies are being conducted or discussed, there is still wide room for new initiatives. We take the opportunity to invite all EBMT members to design and submit new study proposals as well as to participate in our meetings. New proposals may be submitted in a form of synopsis to the ALWP chairman and appropriate subcommittee leaders. Please, find below their list and contact addresses. Unfortunately, we cannot guarantee acceptance of all projects. Before approval they must be evaluated for both scientific value and feasibility. These issues may be discussed during our business meetings held twice a year. The upcoming one is planned during the EBMT Meeting in Valencia, on Monday, 4th April 2016, between 7:00-9:00 AM. All EBMT members are cordially welcome.

The productivity of the ALWP is huge as reflected by the number of scientific publications and meeting abstracts. Below, please find the list of papers published in 2015 as well as oral presentations during the ASH 2015 meeting. I would also like to draw your attention to the ALWP papers, which will be presented during the EBMT 2016 meeting and invite you to participate in the ALWP plenary session (4th April 2016, 09:–15:15, Hall B4).

Apart from the scientific activity, the ALWP is proud of the educational events organized annually in various European countries. The symposia held in Milan 2010 and Warsaw 2011 gave an opportunity for transplanters to

ALWP NEWSletter, February 2016
meet leaders of the AML and ALL national study groups. Such collaboration appears essential for proper interpretation of our results. Subsequent conferences (Milan 2012, Marseille 2013) reviewed modern trends in pharmacotherapy and immunotherapy. The most recent meeting, focused on strategies to reduce the risk of relapse after transplantation, took place in Paris on 28th November 2015 and was very well attended (see program below). Additionally, ALWP recently contributed to organization of another conference held in Paris on 28th January 2016: "Master Classes in Transplantation and Hematology (MATH): Exploring New Frontiers". The next ALWP symposium will be announced soon. Our activity is possible thanks to a collaborative work of all EBMT members who report their data, ALWP data managers (headed by Emmanuelle Polge) and our statisticians (Myriam Labopin and Eric Beohou). We thank you all for your continuous support and wish you brilliant ideas as well as successful, innovative studies.

<table>
<thead>
<tr>
<th>Subcommittee</th>
<th>Leader</th>
<th>e.mail address</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute lymphoblastic leukemia</td>
<td>Sebastian Giebel</td>
<td><a href="mailto:sgiebel@io.gliwice.pl">sgiebel@io.gliwice.pl</a></td>
</tr>
<tr>
<td>Alternative donors</td>
<td>Fabio Ciceri</td>
<td><a href="mailto:ciceri.fabio@hsr.it">ciceri.fabio@hsr.it</a></td>
</tr>
<tr>
<td>Autologous SCT</td>
<td>Norbert Claude Gorin</td>
<td><a href="mailto:norbert-claude.gorin@sat.aphp.fr">norbert-claude.gorin@sat.aphp.fr</a></td>
</tr>
<tr>
<td>Cord blood transplantation</td>
<td>Frederic Baron</td>
<td><a href="mailto:f.baron@ulg.ac.be">f.baron@ulg.ac.be</a></td>
</tr>
<tr>
<td>Immunotherapy</td>
<td>Christoph Schmid</td>
<td><a href="mailto:christoph.schmid@klinikum-augsburg.de">christoph.schmid@klinikum-augsburg.de</a></td>
</tr>
<tr>
<td>Molecular markers</td>
<td>Jordi Esteve</td>
<td><a href="mailto:jesteve@clinic.ub.es">jesteve@clinic.ub.es</a></td>
</tr>
<tr>
<td>Reduced intensity conditioning</td>
<td>Bipin Savani</td>
<td><a href="mailto:bipin.savani@Vanderbilt.Edu">bipin.savani@Vanderbilt.Edu</a></td>
</tr>
</tbody>
</table>

**Chairman**

Arnon Nagler  
Chaim Sheba Medical Center  
Tel-Hashomer, Israel  
Email: arnon.nagler@sheba.health.gov.il

**Secretary**

Sebastian Giebel  
Maria Sklodowska-Curie Memorial Cancer Centre & Institute of Oncology  
Gliwice, Poland  
Email: sgiebel@io.gliwice.pl
**ALWP 2015 PUBLICATIONS**


ALWP ORAL PRESENTATIONS DURING ASH 2015
(Orlando, December 3-6th)


Reduction of Leukemic Relapse after allo-HSCT: How to Move Forward? (PARIS, November 28th, 2015)

Session 1: Bridging to transplant
- Introduction: ALWP chair (Arnon Nagler, Israel) and local host (Mohamad Mohty, France)
- Bite Abs for ALL (Herve Dombret, France)
- Anti FLT3 compounds for AML (Jean Pierre Marie, France)
- Hypomethylating agents (Charles Craddock, UK)

Session 2: Optimizing conditioning
- Novel alkylation agents (Arnon Nagler, Israel)
- Reduced toxicity regimens (Mohamad Mohty, France)
- Novel targeted radiotherapy (Sebastian Giebel, Poland)

Keynote lecture
- Genetic pathogenesis of AML (Brunangelo Falini, Italy)

Session 3: Prevention and treatment of Relapse
- Premptive or prophylactic DLI (Cristoph Schmid, Germany)
- Sequential chemo/AlloHSCT (Frederic Baron, Belgium)
- Second transplant (Bipin Savani, USA)
- Cellular Therapies (Fabio Ciceri, Italy)